First Ascent Biomedical opened a CLIA- and CAP-certified FPM lab in Miami, testing FDA-approved drugs on patient tumor cells with results in ~10 days. Sponsored testing is available for eligible Florida residents and colorectal cancer patients.
A post hoc STAMPEDE analysis found lower on-treatment PSA levels were strongly associated with improved long-term survival in advanced prostate cancer, but disease burden still affected outcomes.
Studies in gastroesophageal and locally advanced rectal cancers linked dynamic ctDNA monitoring to treatment response and prognosis. MRD clearance, more than 90% ctDNA declines, and early ctDNA clearance were associated with better outcomes.
Studies in muscle-invasive bladder cancer found ctDNA predicted metastatic risk after bladder-sparing treatment, while urine tumor DNA was more sensitive for residual bladder disease. Data from RETAIN-2 and a PNAS study support molecular testing to help select patients for bladder preservation.
Atezolizumab combined with chemotherapy shows significant benefits in dMMR/MSI-H colorectal cancer. In stage III disease, the ATOMIC trial demonstrated improved 3-year DFS (86.3% vs 76.2%) with atezolizumab plus mFOLFOX6. For metastatic disease, the COMMIT trial showed superior PFS (24.5 vs 5.3 months) with atezolizumab, bevacizumab, and FOLFOX versus atezolizumab monotherapy.
Mayo Clinic is pursuing two distinct nanoparticle-based cancer treatments: milk-derived nanoparticles for targeted gene therapy in bile duct cancer, and magnetic nanoparticle hyperthermia for metastatic solid tumors.
New research highlights circulating tumor DNA as a prognostic tool in early-stage triple-negative breast cancer, while leronlimab demonstrates long-term survival signals in heavily pretreated metastatic patients through CCR5 receptor blockade.
A computational histology artificial intelligence platform can predict which of two chemotherapy regimens is more effective for individual pancreatic cancer patients, according to a study published in the Journal of Clinical Oncology.
Phase 3 BREAKWATER trial shows encorafenib plus cetuximab and chemotherapy achieved 30.3 months median overall survival versus 15.1 months with standard therapy in previously untreated BRAF V600E-mutant metastatic colorectal cancer.
New ASCO guideline emphasizes biomarker-driven treatment for advanced gastroesophageal cancer, recommending upfront testing for HER2, PD-L1, MSI/MMR, and CLDN18.2 to guide immunotherapy and targeted therapy selection.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07682675 |
Study to Evaluate the Efficacy of Zanzalintinib in the Treatment of Relapsed or Metastatic Adenoid Cystic Carcinomas of the Head and Neck |
NOT_YET_RECRUITING | PHASE2 |
| NCT07627711 |
Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma |
RECRUITING | PHASE1/PHASE2 |
| NCT06856603 |
OLIGO-10: Stereotactic Ablative Radiation Therapy for Metastatic Patients With 6 to 10 Metastatic Sites |
RECRUITING | PHASE2 |
| NCT06424210 |
The Role of Surgery for Esophageal Cancer With Metastatic Disease (M1) |
COMPLETED | |
| NCT05789771 |
Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia. |
COMPLETED | |
| NCT05188911 |
Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial |
UNKNOWN | |
| NCT04595032 |
MAnagement of METastatic Disease in Campania (MAMETIC) |
COMPLETED | |
| NCT04492735 |
The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid Malignancies |
UNKNOWN | |
| NCT04116164 |
Safety and Targeting of Anti-hk2 Antibody in mCRPC |
TERMINATED | EARLY_PHASE1 |
| NCT03823989 |
Intravenously Administered Liposomal PROMITIL in Combination With External Beam Radiotherapy in Cancer Patients |
COMPLETED | PHASE1 |
